On-demand webinar: Semaglutides weight loss drugs

  • 2025年3月27日 2025年3月27日
  • 北美洲, 英国和欧洲

  • Regulatory movement

  • 保险和再保险

Semaglutides are diabetes control drugs, which work by activating glucagon-like peptide-1 (GLP-1) receptors to suppress appetite. In 2021, they began to be marketed for the treatment of obesity.

With brands such as Ozempic becoming household names, Semaglutides are an emerging risk in its early stages, as trials are still underway to determine the full extent of the associated side effects. Given recent precedents in pharmaceutical liability, however, the MDL (Multidistrict litigation) is worth watching closely.

This episode explores the potential risks and lawsuits surrounding Semaglutides, including their side effects and possible implications for insurers.

Watch the recording

结束

掌握其礼的最新消息

注册您的邮箱,获取其礼最新消息!

Navigating the unknown

The latest Insurance Emerging Risk news and opinions from our specialists

Read More